Status:
RECRUITING
A Survey to Assess Participants' and Physicians' Knowledge When Using GATTEX (Knowledge Assessment Survey)
Lead Sponsor:
Takeda
Conditions:
Short Bowel Syndrome (SBS)
Eligibility:
All Genders
18+ years
Brief Summary
The study is about learning and documenting how well participants and physicians understand how to use GATTEX and about potential risks by using a survey (called Knowledge Assessment Survey). This sur...
Eligibility Criteria
Participant inclusion criteria:
Participants who are 18 years of age and who have taken GATTEX in the 60 days prior to survey implementation are eligible to participate in the survey. A caregiver may participate in this survey on behalf of a participant who is eligible but unable to complete the survey. Note: Participants who have previously participated in a GATTEX Patient Knowledge Assessment Survey, are eligible.
Prescriber inclusion criteria:
HCPs (adult and pediatric) in the United States who can provide a 10-digit National Provider Identifier (NPI) number and who have prescribed GATTEX at least once regardless of their completion of the voluntary GATTEX REMS training (Prescriber Education Slide Deck) are eligible for participation in the survey. Note: HCPs who have previously participated in a GATTEX Prescriber Knowledge Assessment Survey, are eligible
Participant and Prescriber exclusion criteria:
- Respondents who do not agree to participate in the survey.
- Respondents who are currently working for and/or whose immediate family members who are currently working for Takeda Pharmaceuticals U.S.A., Inc., NPS Pharmaceuticals, Inc., Shire, UBC, or the Food and Drug Administration (FDA) are not eligible to participate in the survey.
- Respondents who reported having a conflict of interest.
- HCPs who have opted out of receiving communications about the GATTEX Prescriber Knowledge Assessment Survey for the current wave
Further details associated with respondents who do not meet the exclusion criteria established above, will be provided in the assessment report.
Key Trial Info
Start Date :
August 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2031
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT05561647
Start Date
August 1 2013
End Date
December 31 2031
Last Update
January 26 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Takeda Pharmaceuticals, U.S.A., Inc.
Cambridge, Massachusetts, United States, 02142